The current review aims to summarize existing physiological and clinical evidence on the use of SGLT2 inhibitors, CA inhibitors, thiazide diuretics, and MR antagonists in managing HF and their role as adjunctive diuretic agents in the acute and chronic setting. The gene discussed is NR3C2; the disease is hydrops fetalis.